Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing technique may shield heart from failure in block patients

NCT ID NCT04730921

Disease control Sponsor: Fu Wai Hospital, Beijing, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a newer pacing method (left bundle branch area pacing) against the standard method (right ventricular pacing) in 486 adults with atrioventricular block, a condition where the heart's electrical signals are delayed. The goal was to see if the newer method better preserves the heart's pumping ability and reduces risks of death, heart failure hospitalization, or need for advanced pacing therapy. Participants were followed over time to compare outcomes between the two pacing approaches.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

486 people

The number who actually took part.

Started

Nov 2020

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * a. Adult patients aged 18-90; * b. AV block patients with ventricular pacing indications and the expected rate of ventricular pacing(VP)\> 40%, including (a)Third-degree AV block; (b) Second degree AV block (type II); (c) intermittent advanced AV block with expected VP\>40%; (d)Symptomatic first degree AV block and PR interval on ECG ≥ 250ms; * c. The subject is able to receive a pectoral implant; * d. The subject is willing and able to comply with the protocol; * e. The subject is expected to remain available for follow-up visits at the study centers. * f. Subject or authorized legal guardian or representative has signed and dated the study Subject Informed Consent Exclusion Criteria: * a. Baseline echocardiographic assessment of patients with impaired LV function (LVEF\<50%); * b. Having difficulties in follow-up: Those who cannot accept 2-year follow-up on time due to physical condition or other reasons; * c. Patients with persistent atrial fibrillation; * d. Pacemaker replacement without new implanted ventricular electrodes; * e. Patients with implantable cardioverter-defibrillator (ICD) indications; * f. Surgery is required within 1 year due to severe structural heart disease; * g. Patients with tricuspid mechanical valve replacement, or congenital heart disease (including transposition of the great arteries, or permanent left superior vena cava, etc), or AV block resulting from: (a) Hypertrophic cardiomyopathy(HCM)vpost (modified) Morrow surgery, (b) ventricular septal defect repair; and those who are unlikely to achieve successful LBBAP procedure.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrioventricular block are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrioventricular block heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrioventricular block Heart failure Left bundle branch area pacing Right ventricular pacing

Contacts and locations

Locations

  • Beijing Anzhen hospital, Capital Medical University

    Beijing, Beijing Municipality, 100029, China

  • Fuwai Central China Cardiovascular Hospital

    Zhengzhou, Henan, 450003, China

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100037, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Teda International Cardiovascular Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.